Showing results (111-120 of 202) with videos related to
Sort By:
Pageof 21
Future Oncology (London, England)|June 11, 2024
Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choicesAdam Brufsky, Martine C Maculaitis, Lewis Kopenhafer, et al.Breast Cancer Research and Treatment|March 15, 2012
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trialAdam Brufsky, Vicente Valero, Beatrice Tiangco, et al.Pain|October 30, 2018
CACNG2 polymorphisms associate with chronic pain after mastectomyAndrey V Bortsov, Marshall Devor, Mari A Kaunisto, et al.BMC Cancer|September 1, 2017
Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapyTalal Hilal, Mary Nakazawa, Jacob Hodskins, et al.Cancer|May 27, 2023
The feasibility, acceptability, and preliminary efficacy of a self-advocacy serious game for women with advanced breast or gynecologic cancerTeresa Hagan Thomas, Catherine Bender, Heidi S Donovan, et al.The Oncologist|June 3, 2008
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozoleAdam Brufsky, Nigel Bundred, Robert Coleman, et al.Journal of Medical Virology|June 27, 2020
Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19Stephen M Smith, Avinash Boppana, Julie A Traupman, et al.Future Oncology (London, England)|September 1, 2021
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancerAditya Bardia, Sara A Hurvitz, Hope S Rugo, et al.Breast (Edinburgh, Scotland)|March 14, 2026
Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancerAdam Brufsky, Rachel M Layman, Xianchen Liu, et al.International Journal of Surgical Oncology|February 8, 2012
Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastasesSung W Cho, Krit Kitisin, David Buck, et al.Pageof 21